PAR:SIGHT

GenSight Biologics S.A. Stock Insider Trading

Euronext Paris > Healthcare > Biotechnology

0.340€

-0.0050 (-1.45%)

At Close: Jun 26, 2024

GenSight Biologics S.A. Stock Insider Power

Based on the 0 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 0 and sold 0 SIGHT.PA shares in the last 0 trades.

Historical Insider Trades

There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:

Sorry! Image not available at this moment

About GenSight Biologics S.A.

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy... SIGHT.PA Profile

Golden Star

Ticker	Date	Change	Price
EVBG	Jun 21	0.0863%	$34.76
DDOG	Jun 21	1.33%	$117.57
BRK-A	Jun 20	0.575%	$617,249.90
EPD	Jun 18	2.90%	$28.30
USFD	Jun 18	4.33%	$53.14
INTC	Jun 18	0.359%	$30.63
UFPT	Jun 18	2.05%	$253.79
^DJI	Jun 18	0.714%	38,834.86 points
RGA	Jun 17	1.53%	$203.90
MA	Jun 17	1.68%	$448.11

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by

Sign In